BioSpace News Archive

Sonendo, Inc. (NYSE: SONX), a leading dental technology company and developer of the GentleWave® System, today announced a private placement of common stock and pre-funded warrants, resulting in gross proceeds of $63 million.

Soligenix encourages all stockholders of record at the close of business on July 25, 2022 who have not yet voted, to vote by 11:59 p.m., Eastern Time on October 18, 2022.

Wellbeing Digital Sciences Inc. will participate in Microdose’s Psychedelic Capital: September 2022 Conference to be held virtually on September 29, 2022 at 1:30 p.m. ET.

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today announced the publication of a children’s book developed in collaboration with the Bardet-Biedl Syndrome (BBS) Foundation.

Alimera Sciences, Inc. announces that it has entered into an agreement with the Jaeb Center for Health Research Foundation Inc. (JCHR), acting on the behalf of the DRCR Retina Network.

Jasper Therapeutics, Inc. today announced that the Company will be participating in the following conferences in September.

Immutep Limited is pleased to announce it has received a €1,804,341 (~ A$2,693,046 ) research and development (R&D) tax incentive payment in cash from the French Government under its Crédit d’Impôt Recherche scheme (CIR).

Adverum Biotechnologies, Inc. today announced that data from the OPTIC trial of ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022) in wet age-related macular degeneration (wet AMD) will be presented next week during the Late Breaking Developments portion of Retinal Subspecialty Day.

Wugen, Inc. today announced that management will participate in a fireside chat at 1:30 p.m. ET on Friday, September 30, 2022 at the upcoming Jefferies Cell & Genetic Medicine Summit set to take place in New York City.

Leuko, an MIT startup developing PointCheckTM, the first solution that enables at-home noninvasive white blood cell (WBC) monitoring, today announced a first closing of $5 million for their Series A round.